INTERNATIONAL BIOTECHNOLOGY TRUST PLC (the Company)
Portfolio Update as at 28 February 2018
Net Assets |
£227m |
Net Assets per share |
605p |
Share price |
586p |
Total value of unquoted investments |
£22m |
Total number of portfolio companies |
95 |
Dividend |
4% of NAV per annum |
Top Ten Quoted Investments
Company Name |
% NAV |
Array |
4.7 |
Biogen |
4.2 |
Celgene |
4.2 |
Neurocrine |
4.2 |
Regeneron |
3.7 |
Genmab |
3.7 |
Sage |
3.6 |
Vertex |
3.6 |
Gilead |
3.3 |
Exelixis |
3.2 |
|
----------- |
Total |
38.4 |
Geographical Allocation |
% NAV |
US & Canada |
89 |
Europe & UK |
11 |
|
----------- |
Total |
100 |
Quoted/Unquoted Allocation |
% NAV |
Quoted |
91 |
Unquoted |
9 |
|
----------- |
Total |
100 |
NAV % Market Cap |
% NAV |
Large Cap >USD10BN |
36 |
Mid Cap =USD1-10BN |
37 |
Small Cap <USD1BN |
27 |
|
----------- |
Total |
100 |
NAV % by Therapeutic Areas |
% NAV |
Oncology |
38 |
Rare diseases |
15 |
CNS |
14 |
Inflammation |
6 |
Ophthalmology |
6 |
Metabolic |
5 |
Infectious Diseases |
4 |
Medtech |
4 |
Other |
8 |
|
----------- |
Total |
100 |
BNP Paribas Secretarial Services Limited
Company Secretary
21 MARCH 2018